Our darling Sam was diagnosed with MS at 5 years old, Sam is now 7, he will be 8 in October.

Sam has made his Dad and myself smile again, if you told us that 2 years ago I would never ever have believed it. But Sam has not had a clinical relapse since August 2009, we've had lots of scares and tears but I've learnt MS is so so wierd, you can havesymptoms ...

Acorda Therapeutics, Inc. announced an analysis of pooled clinical trial results showed patients who were responders to Ampyra® (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.

The data were presented at the 2011 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, ...

Reversing an earlier decision, European regulators have recommended approving Acorda Therapeutics Inc's (ACOR.O) drug Fampyra, which is designed to improve the walking ability of patients with multiple sclerosis.

Acorda shares jumped 21 percent to $32.33 in premarket trading on Friday.

The European Medicines Agency, which advises the European Commission on whether to approve new drugs, said in a statement it has recommended giving the drug conditional approval.... Read More - ...

The Australian Therapeutic Goods Administration (TGA) has granted approval for Fampyra™, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

Fampyra demonstrated efficacy in people with all four majortypes of MS (relapsing remitting, secondary progressive, progressive relapsing and primary progressive). Fampyra can be used alone or with existing MS therapies, including immunomodulator drugs..... ...

Acorda Therapeutics, Inc. today announced data analyses showing that people with multiple sclerosis (MS) who responded to Ampyra™ (dalfampridine) Extended Release Tablets, 10 mg had comparable improvements in their walking regardless of baseline walking speed or overall level of MS-related disability1.

In addition, Ampyra responders, regardless of baseline disability, showed clinically meaningful improvement on the 12-Item MS Walking Scale (MSWS-12), a patient-based questionnaire that measures the impact of MS on the patient's reported ability ...

I am really eager to try that; as it is said to help a lot in movements issues. It will probably not make me walk; but if it might help with my arms I would be already very happy to resume working on-line :?

Ampyra is not available here yet; and I could not find any pharmacist willing to compound 4-AP for me; as it is a ...